Mairead G McNamara
@mgmcnamara
Med Oncologist (HPB/NET), @OfficialUoM @UoM_DCS & @TheChristieNHS, ASCO ESP graduate via @uniofgalway @ucc 🇮🇪 & Princess Margaret, Toronto 🇨🇦 #UKINETS #ASCO
ID: 1702794371811217408
15-09-2023 21:26:51
341 Tweet
304 Followers
348 Following
🚨🥁ANNOUNCEMENT: Precision medicine & tumor-agnostic drug development take center stage ESMO - Eur. Oncology #ESMO24 ! ‼️👉Honored to be invited to speak at the SPECIAL ESMO & ASCO joint session in Barcelona, Spain on "Tumour-agnostic drug development" at the ESMO congress 2024. 👉Chaired
📢Hepatopancreaticobiliary-NET abstracts in #ESMO24 ESMO - Eur. Oncology ➡️HCC ✅LBA3 - Transarterial Chemoembolization (TACE) With or Without Lenvatinib (len) + Pembrolizumab (pembro) for Intermediate-Stage Hepatocellular Carcinoma (HCC): Phase 3 LEAP-012 Study ✅LBA38 - Iparomlimab and
The first prospective evidence on neoadjuvant RLT for pancreatic NET is finally out on BJS .Great team work from eight Italian centers 🇮🇹 ENETS NANETS NET Cancer Day Neuroendocrine Cancer UK #NotJustNECancer Neuroendocrine Cancer NET CANCER FOUNDATION NETs México NET Research Foundation NETwerk NET- ESPAÑA
Impact of Adjuvant Chemotherapy on Resected IPMN-Derived #pancsm should we omit adjuvant chemo in N0, CA19.9 low cases? Prospective data are needed Journal of Clinical Oncology ascopubs.org/doi/abs/10.120…
Updated data for atezo + bev vs surveillance in resected or ablated high risk HCC #ESMO24 🔎IMbrave050 👉RFS 33.2 vs 36 mo, HR 0.9 👉OS: HR: 1.26 🧐Benefit not sustained! Disappointing.. 🧐Caveat of (too) early read outs… ESMO - Eur. Oncology #ESMOAmbassadors @ILCA EASL Education
PANDAS PRODIGE 44 BR-PDAC ➡️mFFX vs mFFX + caperads 50.4Gy ➡️No diff in R0 resection rate ➡️No diff in mOS 32.8 vs 30mths ➡️numerically longer locoregional recurrence rate in RT arm but not sig ‼️imp to note in those randomised how many get to adjuvant ~50% #ESMO2024 HPB Dublin
Informative session on CUP #ESMO24 ESMO - Eur. Oncology Natalie Cook 💙 with recent publication of CUPISCO trial leading to changes in ESMO guidelines; benefit of molecularly guided therapies and importance of molecular profiling The Christie NHS Manchester Cancer Research Centre
Points highlighted and controversies in BTC discussed by Profs Lowery & Chan #ESMO2024 ; liquid biopsy may miss FGFR2 fusions, role for transplant/loco regional Rx in CCA, sequencing of FGFR2 inhibitors, rise in early onset BTC-metabolic factors? ESMO - Eur. Oncology
Lovely night at the MCRC - The Christie, Manchester #ESMO2024 Academic reception in Barcelona Natalie Cook 💙 Manchester Cancer Research Centre The Christie NHS ESMO - Eur. Oncology
Ready for another great day at #ESMO24! This morning Robin Zon, MD, FACP, FASCO is co-chairing w Andres Cervantes a session at which our CMO Julie Gralow is speaking, “Novel Pathways for Development of Precision Therapeutics in Molecular Oncology” w/ Dr. Gralow focusing on “regulatory sandboxes.”
Timely/topical ASCO @ESMO session #ESMO24 on potential pt benefit of organoids, challenges of tumour agnostic/accelerated approvals, cautious optimism around AI & accessibility issues; LMIC issues probably worse Herbert Loong, MBBS, FASCO Vivek Subbiah, MD Robin Zon, MD, FACP, FASCO Julie Gralow
Dilemmas in HPB cancers discussed ESMO - Eur. Oncology #ESMO2024 ; 5 yr survival in HCC 50-70%; need for neo-adjuvant/adjuvant success. What to do in special subgroups in HCC & BTC re: immunotherapy, & need for immuno bio markers in both groups Lorenza Rimassa Arndt Vogel
Updated discussion on Checkmate 9DW & HIMALAYA in 1L advanced HCC ESMO - Eur. Oncology #ESMO2024; why TKI arm does better earlier in Checkmate & improving OS for TKIs over time; pt selection? Further treatment options? More options for pts Lorenza Rimassa ILCA
📢 #ESMO24 concomitant paper: First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase 1 dose exploration. #ESMO24 Hans Prenen tinyurl.com/23btbhxd
I'm excited to see this early data at #ESMO24 on AMG 193 for my patients with pancreas, biliary & oesophageal cancer 👏👏 MTAP deletion is a new target for hard to treat cancers annalsofoncology.org/article/S0923-… #Presidential ESMO - Eur. Oncology